The BioNTech SE ADR BNTX rose 1.18% to $115.30 Thursday, on what proved to be an all-around rough trading session for the ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, ...

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biontech SE agreed to pay up to nearly $1.26 billion in two separate settlements to resolve royalty disputes with the U.S. NIH and the University of Pennsylvania related to the COVID-19 vaccine the ...

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid.